MX2020002032A - Inhibidores de bcl-2. - Google Patents
Inhibidores de bcl-2.Info
- Publication number
- MX2020002032A MX2020002032A MX2020002032A MX2020002032A MX2020002032A MX 2020002032 A MX2020002032 A MX 2020002032A MX 2020002032 A MX2020002032 A MX 2020002032A MX 2020002032 A MX2020002032 A MX 2020002032A MX 2020002032 A MX2020002032 A MX 2020002032A
- Authority
- MX
- Mexico
- Prior art keywords
- sub
- bcl
- inhibitors
- disease
- compounds
- Prior art date
Links
- 239000012664 BCL-2-inhibitor Substances 0.000 title 1
- 229940123711 Bcl2 inhibitor Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 230000001613 neoplastic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/14—Ortho-condensed systems
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/75—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
- G01N21/76—Chemiluminescence; Bioluminescence
- G01N21/763—Bioluminescence
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Physics & Mathematics (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Plasma & Fusion (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La descripcion incluye compuestos de Formula (A): (ver Fórmula A) en donde R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, y R12, j, k, m, n, Y, W, W1, W2, W3, V, L, Z1, Q1, Q2, Q3, y Q4, se definen en la presente; también se describe un método para tratar una enfermedad neoplasica, una enfermedad autoinmune o una enfermedad neurodegenerativa con estos compuestos.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762549081P | 2017-08-23 | 2017-08-23 | |
| US201862615007P | 2018-01-09 | 2018-01-09 | |
| PCT/US2018/047444 WO2019040573A1 (en) | 2017-08-23 | 2018-08-22 | Bcl-2 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020002032A true MX2020002032A (es) | 2020-09-17 |
Family
ID=63490700
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020002032A MX2020002032A (es) | 2017-08-23 | 2018-08-22 | Inhibidores de bcl-2. |
| MX2020002033A MX2020002033A (es) | 2017-08-23 | 2018-08-22 | Derivados heterociclicos condensados como inhibidores de bcl-2 para el tratamiento de enfermedades neoplasticas. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020002033A MX2020002033A (es) | 2017-08-23 | 2018-08-22 | Derivados heterociclicos condensados como inhibidores de bcl-2 para el tratamiento de enfermedades neoplasticas. |
Country Status (16)
| Country | Link |
|---|---|
| US (8) | US11279711B2 (es) |
| EP (3) | EP3672975B1 (es) |
| JP (2) | JP7467332B2 (es) |
| KR (2) | KR102705861B1 (es) |
| CN (4) | CN116621860A (es) |
| AU (2) | AU2018321496B2 (es) |
| CA (2) | CA3073446A1 (es) |
| DK (2) | DK3672975T3 (es) |
| ES (2) | ES2948287T3 (es) |
| FI (2) | FI3672975T3 (es) |
| IL (1) | IL272762B2 (es) |
| MX (2) | MX2020002032A (es) |
| NZ (1) | NZ762503A (es) |
| SG (1) | SG11202001553UA (es) |
| WO (2) | WO2019040573A1 (es) |
| ZA (1) | ZA202001301B (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2020002032A (es) | 2017-08-23 | 2020-09-17 | Guangzhou Lupeng Pharmaceutical Company Ltd | Inhibidores de bcl-2. |
| CN112437772B (zh) | 2018-04-29 | 2023-11-21 | 百济神州有限公司 | Bcl-2抑制剂 |
| US11903950B2 (en) | 2018-08-22 | 2024-02-20 | Newave Pharmaceutical Inc. | BCL-2 inhibitors |
| WO2020140005A2 (en) | 2018-12-29 | 2020-07-02 | Newave Pharmaceutical Inc. | Bcl-2 inhibitors |
| WO2021066873A1 (en) | 2019-10-03 | 2021-04-08 | Newave Pharmaceutical Inc. | Condensed heterocycles as bcl-2 inhibitors |
| WO2021083135A1 (en) * | 2019-10-28 | 2021-05-06 | Beigene, Ltd. | Bcl-2 INHIBITORS |
| US12552784B2 (en) | 2019-12-27 | 2026-02-17 | Newave Pharmaceutical Inc. | 1H-pyrrolo[2,3-b]pyridine derivatives as BCL-2 inhibitors for the treatment of neoplastic and autoimmune diseases |
| WO2021133817A1 (en) | 2019-12-27 | 2021-07-01 | Guangzhou Lupeng Pharmaceutical Company Ltd. | 1h-pyrrolo[2,3-b]pyridine derivatives as bcl-2 inhibitors for the treatment of neoplastic and autoimmune diseases |
| MX2022010410A (es) * | 2020-02-24 | 2022-12-07 | Guangzhou Lupeng Pharmaceutical Company Ltd | Dispersiones de sólidos con extrusión por termofusión que contienen un inhibidor bcl2. |
| CN116969937B (zh) | 2020-04-15 | 2026-03-24 | 百济神州(苏州)生物科技有限公司 | Bcl-2抑制剂 |
| US20240166646A1 (en) | 2020-12-22 | 2024-05-23 | Newave Pharmaceutical Inc. | 1h-pyrrolo[2,3-b]pyridine derivatives as bcl-2 inhibitors for the treatment of neoplastic and autoimmune diseases |
| CN113694059B (zh) * | 2021-03-24 | 2023-09-26 | 浙江大学 | Nl101在制备治疗急性、慢性排斥反应药物中的应用 |
| WO2023122000A1 (en) * | 2021-12-20 | 2023-06-29 | Newave Pharmaceutical Inc. | Bcl-2 inhibitors |
| WO2023121713A1 (en) * | 2021-12-20 | 2023-06-29 | New Ave Pharmaceutical Inc. | Bcl-2 inhibitors |
| TW202340210A (zh) | 2022-01-21 | 2023-10-16 | 美商艾伯維有限公司 | １，３，４，７－四氫－２Ｈ－吡咯并［３＇，２＇：５，６］吡啶并［２，３－ｂ］［１，４］氮呯Ｂｃｌ－２抑制劑 |
| CN116236583A (zh) * | 2023-03-30 | 2023-06-09 | 广州麓鹏制药有限公司 | 一种含Bcl-2/Bcl-xl抑制剂的组合物及其制备方法与应用 |
| CN116270660A (zh) * | 2023-03-30 | 2023-06-23 | 广州麓鹏制药有限公司 | 一种含Bcl-2/Bcl-xl抑制剂的组合物及其制备方法与应用 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| JP4336678B2 (ja) | 2003-09-04 | 2009-09-30 | 株式会社日立超エル・エス・アイ・システムズ | 半導体装置 |
| WO2005049593A2 (en) | 2003-11-13 | 2005-06-02 | Abbott Laboratories | N-acylsulfonamide apoptosis promoters |
| US8614318B2 (en) | 2003-11-13 | 2013-12-24 | Abbvie Inc. | Apoptosis promoters |
| US7973161B2 (en) | 2003-11-13 | 2011-07-05 | Abbott Laboratories | Apoptosis promoters |
| US7767684B2 (en) | 2003-11-13 | 2010-08-03 | Abbott Laboratories | Apoptosis promoters |
| US7642260B2 (en) | 2003-11-13 | 2010-01-05 | Abbott Laboratories, Inc. | Apoptosis promoters |
| US20080182845A1 (en) | 2006-11-16 | 2008-07-31 | Abbott Laboratories | Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection |
| GB0623209D0 (en) * | 2006-11-21 | 2007-01-03 | F2G Ltd | Antifungal agents |
| WO2009036035A1 (en) | 2007-09-10 | 2009-03-19 | Curis, Inc. | Bcl-2 inhibitors |
| NZ585085A (en) | 2007-11-16 | 2012-08-31 | Abbott Lab | Method of treating arthritis using arylsulfonamide compounds |
| US8557983B2 (en) | 2008-12-04 | 2013-10-15 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| UA108193C2 (uk) | 2008-12-04 | 2015-04-10 | Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань | |
| US20100160322A1 (en) | 2008-12-04 | 2010-06-24 | Abbott Laboratories | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| NZ614305A (en) | 2008-12-05 | 2015-03-27 | Abbvie Inc | Sulfonamide derivatives as bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
| US8563735B2 (en) | 2008-12-05 | 2013-10-22 | Abbvie Inc. | Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
| US8586754B2 (en) | 2008-12-05 | 2013-11-19 | Abbvie Inc. | BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
| US9034875B2 (en) | 2009-05-26 | 2015-05-19 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| ES2546294T7 (es) | 2009-05-26 | 2024-06-06 | Abbvie Ireland Unlimited Co | Agentes inductores de la apoptosis para el tratamiento de cáncer y enfermedades inmunitarias y autoinmunitarias |
| US8546399B2 (en) | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
| TWI520960B (zh) | 2010-05-26 | 2016-02-11 | 艾伯維有限公司 | 用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘導劑 |
| JP5743482B2 (ja) | 2010-10-15 | 2015-07-01 | 株式会社アルファ | エスカッション部材のハンドルベースへの連結方法 |
| UA113500C2 (xx) | 2010-10-29 | 2017-02-10 | Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб | |
| KR20180059560A (ko) | 2010-10-29 | 2018-06-04 | 애브비 인코포레이티드 | 아폽토시스―유도제를 포함하는 고체 분산체 |
| WO2012071336A1 (en) | 2010-11-23 | 2012-05-31 | Abbott Laboratories | Salts and crystalline forms of an apoptosis-inducing agent |
| EP2935284A4 (en) * | 2012-12-21 | 2016-04-27 | Abbvie Inc | HETEROCYCLIC MODULATORS OF HORMONE NUCLEAR RECEPTORS |
| RS57569B1 (sr) | 2013-03-13 | 2018-10-31 | Abbvie Inc | Postupci za pripremanje agensa koji uzrokuje apoptozu |
| CN104513259B (zh) * | 2013-09-26 | 2017-06-16 | 广东东阳光药业有限公司 | 取代脲衍生物及其在药物中的应用 |
| WO2017132474A1 (en) | 2016-01-30 | 2017-08-03 | Newave Pharmaceutical Inc. | Bcl-2 inhibitors |
| CN110177788B (zh) | 2017-01-07 | 2023-03-24 | 重庆复创医药研究有限公司 | 作为bcl-2选择性凋亡诱导剂的化合物 |
| SI3612531T1 (sl) | 2017-04-18 | 2022-11-30 | Shanghai Fochon Pharmaceutical Co., Ltd. | Sredstva, ki sprožajo apoptozo |
| MX2020002032A (es) | 2017-08-23 | 2020-09-17 | Guangzhou Lupeng Pharmaceutical Company Ltd | Inhibidores de bcl-2. |
| US11903950B2 (en) | 2018-08-22 | 2024-02-20 | Newave Pharmaceutical Inc. | BCL-2 inhibitors |
| WO2020140005A2 (en) | 2018-12-29 | 2020-07-02 | Newave Pharmaceutical Inc. | Bcl-2 inhibitors |
| WO2021066873A1 (en) | 2019-10-03 | 2021-04-08 | Newave Pharmaceutical Inc. | Condensed heterocycles as bcl-2 inhibitors |
| US12552784B2 (en) | 2019-12-27 | 2026-02-17 | Newave Pharmaceutical Inc. | 1H-pyrrolo[2,3-b]pyridine derivatives as BCL-2 inhibitors for the treatment of neoplastic and autoimmune diseases |
-
2018
- 2018-08-22 MX MX2020002032A patent/MX2020002032A/es unknown
- 2018-08-22 WO PCT/US2018/047444 patent/WO2019040573A1/en not_active Ceased
- 2018-08-22 EP EP18765254.0A patent/EP3672975B1/en active Active
- 2018-08-22 CN CN202310439771.XA patent/CN116621860A/zh active Pending
- 2018-08-22 AU AU2018321496A patent/AU2018321496B2/en active Active
- 2018-08-22 CN CN202310267471.8A patent/CN116425771A/zh active Pending
- 2018-08-22 DK DK18765254.0T patent/DK3672975T3/da active
- 2018-08-22 IL IL272762A patent/IL272762B2/en unknown
- 2018-08-22 CN CN201880067225.5A patent/CN111511748B/zh active Active
- 2018-08-22 NZ NZ762503A patent/NZ762503A/en unknown
- 2018-08-22 JP JP2020510610A patent/JP7467332B2/ja active Active
- 2018-08-22 EP EP23167453.2A patent/EP4227311A1/en active Pending
- 2018-08-22 EP EP18765259.9A patent/EP3672976B1/en active Active
- 2018-08-22 AU AU2018322059A patent/AU2018322059C1/en active Active
- 2018-08-22 KR KR1020207008178A patent/KR102705861B1/ko active Active
- 2018-08-22 CA CA3073446A patent/CA3073446A1/en active Pending
- 2018-08-22 CA CA3073445A patent/CA3073445A1/en active Pending
- 2018-08-22 ES ES18765254T patent/ES2948287T3/es active Active
- 2018-08-22 SG SG11202001553UA patent/SG11202001553UA/en unknown
- 2018-08-22 KR KR1020207008179A patent/KR102680163B1/ko active Active
- 2018-08-22 CN CN201880067185.4A patent/CN111448198B/zh active Active
- 2018-08-22 MX MX2020002033A patent/MX2020002033A/es unknown
- 2018-08-22 WO PCT/US2018/047411 patent/WO2019040550A1/en not_active Ceased
- 2018-08-22 DK DK18765259.9T patent/DK3672976T3/da active
- 2018-08-22 FI FIEP18765254.0T patent/FI3672975T3/fi active
- 2018-08-22 FI FIEP18765259.9T patent/FI3672976T3/fi active
- 2018-08-22 ES ES18765259T patent/ES2971457T3/es active Active
- 2018-08-22 JP JP2020510576A patent/JP7467331B2/ja active Active
-
2020
- 2020-02-20 US US16/795,884 patent/US11279711B2/en active Active
- 2020-02-20 US US16/795,720 patent/US11365206B2/en active Active
- 2020-02-28 ZA ZA2020/01301A patent/ZA202001301B/en unknown
-
2022
- 2022-03-18 US US17/698,289 patent/US11680072B2/en active Active
- 2022-06-15 US US17/840,957 patent/US11993610B2/en active Active
-
2023
- 2023-05-03 US US18/142,842 patent/US12410190B2/en active Active
-
2024
- 2024-04-22 US US18/641,869 patent/US20240425520A1/en not_active Abandoned
- 2024-12-06 US US18/971,214 patent/US20250179090A1/en active Pending
-
2025
- 2025-01-17 US US19/027,649 patent/US20260152513A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020002033A (es) | Derivados heterociclicos condensados como inhibidores de bcl-2 para el tratamiento de enfermedades neoplasticas. | |
| WO2017132474A8 (en) | Bcl-2 inhibitors | |
| PH12021500014A1 (en) | Fused ring compounds | |
| PH12020500655A1 (en) | Compounds | |
| MX2021006011A (es) | Un inhibidor de la quinasa aurora a para su uso en el tratamiento del neuroblastoma. | |
| WO2020041405A8 (en) | Bcl-2 inhibitors | |
| WO2021066873A8 (en) | Condensed heterocycles as bcl-2 inhibitors | |
| MY203303A (en) | Compounds | |
| SG11201909186YA (en) | Triazole silane compound, method for synthesizing said compound and use thereof | |
| WO2021022163A3 (en) | Compounds and uses thereof | |
| AU2017382297A8 (en) | Phosphodiesterase inhibitors and methods of microbial treatment | |
| WO2018042343A3 (en) | Compounds that inhibit 3c and 3cl proteases and methods of use thereof | |
| MX383935B (es) | Amidas heterocíclicas como inhibidores de cinasa. | |
| EA202193015A1 (ru) | Ингибиторы cdk | |
| MX2021012973A (es) | Sustituto de huevo y composiciones que comprenden el sustituto de huevo y metodos para producir el mismo. | |
| CR20220156A (es) | Anticuerpos anti-klk7, anticuerpos anti-klk5, anticuerpos multiespecíficos anti-klk5/klk7 y métodos de uso | |
| MX2021003819A (es) | Moduladores de alfa-1 antitripsina. | |
| GEP20227443B (en) | Magl inhibitors | |
| TN2019000211A1 (en) | Antitumoral compounds | |
| MX2020008627A (es) | Inhibidores de btk y mutantes de los mismos. | |
| SG11201906435SA (en) | Pyrimidine compound and pharmaceutical use thereof | |
| JOP20190190A1 (ar) | معالجة سرطان | |
| MX2019011116A (es) | Inhibidores de la tirosina quinasa de bruton. | |
| MX2020008678A (es) | Metodos de uso para derivados de benzotriazol trisustituidos. | |
| MX2022007626A (es) | Combinaciones. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GB | Transfer or rights |
Owner name: GUANGZHOU LUPENG PHARMACEUTICAL COMPANY LTD. |